Qlarity Imaging teams with Blackford to improve breast MRI accuracy

Qlairty will merge its AI-powered diagnostic software with Blackford’s centralized imaging platform

Woman talking with a nurse while sitting on a table for an MRI machine

Qlarity Imaging and Blackford have signed a new pact to improve breast magnetic resonance imaging (MRI) accuracy.

QuantX by Qlarity Imaging differentiates benign from malignant breast lesions by synthesizing 34 radiomic features into a single value. The QuantX Score, derived from analysis of proven lesions, indicates the likelihood of malignancy in a specimen. The FDA-cleared artificial intelligence (AI) also assists radiologists with volumetric and surface area measurements.

Per the new deal, Qlarity will integrate its AI diagnostic software with Blackford’s centralized imaging platform to help radiologists and health care systems achieve better clinical outcomes.

The Qlarity-Blackford partnership is also geared toward reducing breast MRI deployment time, costs, maintenance, monitoring, and support requirements.

"Breast MRI evaluations are one of the more difficult exams for radiologists. Factoring in the current challenges contributing to widespread radiologist burnout, the question is not if technological advancements are needed, but how they can be developed and implemented to add the most value," said Jon DeVries, Qlarity Imaging CEO

DeVries added, "Partnering with Blackford will help radiologists and their teams overcome current workflow, budget, and productivity challenges, while also providing unique opportunities for innovation with partners to improve the quality of breast cancer screening and diagnosis strategies."

Related Resource

Preparing for AI-enabled cyber attacks

MIT technology review insights

AI icon against a laptop icon on a yellow background - whitepaper from DarktraceDownload now

Commenting on its tool’s scope, Qlarity stated QuantX is designed for screening patients at high risk for breast abnormalities. QuantX's clinical trials that earned it FDA approval found it reduced missed cancers by 39% and increased clinical accuracy by 20%.

QuantX is not intended for the primary interpretation of digital mammograms. 

"We are delighted that Qlarity's QuantX™ will be available through Blackford's curated marketplace of applications. We look forward to working with Qlarity to provide our customers and channel partners with simplified access to QuantX™ through our dedicated platform, to help drive additional clinical value for patients," said Ben Panter, Blackford Analysis CEO. 

Featured Resources

Modern governance: The how-to guide

Equipping organisations with the right tools for business resilience

Free Download

Cloud operational excellence

Everything you need to know about optimising your cloud operations

Watch now

A buyer’s guide to board management software

Improve your board’s performance

The real world business value of Oracle autonomous data warehouse

Lead with a 417% five-year ROI

Download now

Recommended

The many faces of artificial intelligence
Sponsored

The many faces of artificial intelligence

15 Dec 2021
Industry "delighted" with UK's 'landmark' anti-bias AI standard
artificial intelligence (AI)

Industry "delighted" with UK's 'landmark' anti-bias AI standard

30 Nov 2021
Sophos Intercept X Advanced review: AI-powered protection
endpoint security

Sophos Intercept X Advanced review: AI-powered protection

30 Nov 2021
Vast majority of US healthcare web apps vulnerable to attack
network security

Vast majority of US healthcare web apps vulnerable to attack

24 Nov 2021

Most Popular

Dell XPS 15 (2021) review: The best just got better
Laptops

Dell XPS 15 (2021) review: The best just got better

14 Jan 2022
Sony pulls out of MWC 2022
Business operations

Sony pulls out of MWC 2022

14 Jan 2022
How to speed up Windows 11
Microsoft Windows

How to speed up Windows 11

7 Jan 2022